Clinical Competition Candidate

APRISO

Gastroenterology · Ulcerative colitis, maintenance of remission

APRISO carries use-code patent, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 46 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

46months

to latest listed patent expiry (May 1, 2030)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (none)

Use-code patent (listed)

Patent count: 1

Complexity score: 1/5

Clinical competition

Score: 5/5

Active trials linked: 286

Phase 2/3 trials: 147

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: MESALAMINE

Applicant (NDA holder): SALIX PHARMACEUTICALS INC

Confidence: High

Market context

Therapeutic area: Gastroenterology

Indication: Ulcerative colitis, maintenance of remission

U.S. market size (est.)< $100M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.